Which medication for heart failure with reduced ejection fraction is most effective at reducing mortality: sacubitril/valsartan (Entresto), metoprolol succinate, or spironolactone (Aldactone)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 15, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Entresto (Sacubitril/Valsartan) is Most Effective at Reducing Mortality in HFrEF

For patients with heart failure and reduced ejection fraction (EF ≤40%), Entresto (sacubitril/valsartan) demonstrates superior mortality reduction compared to metoprolol or spironolactone when examined as individual agents. The PARADIGM-HF trial showed Entresto reduced all-cause mortality by 16% (HR 0.84, p=0.0009) and cardiovascular death by 20% (HR 0.80) compared to enalapril, with these benefits driven entirely by lower cardiovascular mortality 1.

Evidence Hierarchy and Comparative Effectiveness

Entresto's Mortality Benefit

The FDA label for Entresto, based on the landmark PARADIGM-HF trial (8,442 patients, mean LVEF 29%), demonstrates:

  • All-cause mortality reduction: HR 0.84 (95% CI 0.76-0.93, p=0.0009)
  • Cardiovascular death reduction: HR 0.80 (95% CI 0.71-0.89)
  • HF hospitalization reduction: HR 0.79 (95% CI 0.71-0.89)
  • Number needed to treat to prevent one death = 35 1

This represents a 16% relative risk reduction in all-cause mortality over a median 27-month follow-up, with benefits consistent across diverse subgroups including age, gender, NYHA class, and baseline medications 1.

Spironolactone's Mortality Benefit

The RALES trial (1,663 patients, median LVEF 26%) showed spironolactone reduced:

  • All-cause mortality by 30% (p<0.001,95% CI 18-40%)
  • Cardiac hospitalizations by 30% (p<0.001,95% CI 18-41%) 2

However, this was compared to placebo, not head-to-head against Entresto. The mean daily dose was only 26 mg, and 100% of patients were on loop diuretics with 95% on ACE inhibitors at baseline 2.

Metoprolol's Mortality Benefit

The 2022 AHA/ACC/HFSA guidelines cite the BBmeta-HF meta-analysis showing beta-blockers reduce all-cause and cardiovascular mortality in HFrEF 3, 4. However, no specific mortality hazard ratio for metoprolol alone is provided in the guideline evidence, and beta-blockers are considered foundational therapy to be used in combination with other GDMT agents.

Critical Clinical Context: These Are Not Alternatives

The fundamental error in this question is treating these medications as mutually exclusive choices. The 2022 AHA/ACC/HFSA guidelines explicitly recommend all three drug classes as guideline-directed medical therapy (GDMT) that should be used together 3, 4:

  • Class 1 recommendation: Continue GDMT even in patients who become asymptomatic to prevent relapse 3
  • 94% of PARADIGM-HF patients were on beta-blockers and 58% on mineralocorticoid antagonists when Entresto demonstrated its mortality benefit 1
  • Discontinuation of any GDMT component increases mortality risk 4

Algorithmic Approach to Mortality Reduction in HFrEF

  1. Initiate all four pillars of GDMT simultaneously or in rapid sequence:

    • ARNI (Entresto preferred over ACE-I/ARB)
    • Beta-blocker (metoprolol succinate, carvedilol, or bisoprolol)
    • Mineralocorticoid receptor antagonist (spironolactone or eplerenone)
    • SGLT2 inhibitor

  2. Prioritize Entresto over ACE-I/ARB for the ARNI component, as it provides the strongest single-agent mortality benefit with a 16% reduction in all-cause mortality 1

  3. Do not withhold or discontinue beta-blockers or MRAs when starting Entresto—these work synergistically 4

  4. Uptitrate all agents to target doses as tolerated, though recent evidence suggests intermediate doses may provide comparable benefit 5

Important Caveats

  • Spironolactone's 30% mortality reduction in RALES was against placebo in an era before widespread ARNI use 2. Its incremental benefit when added to modern GDMT (including Entresto) is likely smaller but still meaningful for hospitalization reduction.

  • Metoprolol's mortality benefit is well-established but not quantified as a standalone comparison in the provided guidelines 3, 4. It remains essential as part of comprehensive therapy.

  • Hypotension is more common with Entresto (15.9% with SBP <100 mmHg in one study) 6, but guidelines emphasize not withholding GDMT for mild blood pressure reductions 4

  • Contraindications are rare: Advanced AV block for beta-blockers (without pacemaker), cardiogenic shock, angioedema for ARNI, or baseline potassium >5.0 mEq/L for spironolactone 4, 2

The answer is Entresto for single-agent mortality reduction, but optimal care requires using all three medication classes together as comprehensive GDMT 3, 4.

References

Related Questions

What are the benefits of sacubitril (in the sacubitril/valsartan combination, brand name Entresto) for patients with heart failure with reduced ejection fraction?
In a 58-year-old patient presenting with progressive dyspnea and paroxysmal nocturnal dyspnea, whose echocardiogram shows anterior wall hypokinesia and a left ventricular ejection fraction of 30%, what is the next best investigation?
In a 65-year-old male with dilated cardiomyopathy (left ventricular ejection fraction 29%) on oral torsemide, spironolactone, sacubitril/valsartan, and aspirin who presents with sudden hypotension and chest tightness (and has been started on norepinephrine infusion and BiPAP), what is the diagnosis and appropriate treatment including drug dosages?
Do levothyroxine, empagliflozin (Jardiance), sacubitril/valsartan (Entresto), and tramadol cause gastrointestinal pain?
In a 64-year-old man with heart failure whose left ventricular ejection fraction has recovered to 50% and who is taking valsartan 20 mg, spironolactone 25 mg, carvedilol 3.125 mg, and furosemide (Lasix) 40 mg, how should symptomatic hypotension be managed?
What are the assessment signs for bacterial meningitis?
Do patients taking a GLP‑1 receptor agonist need to continue it lifelong?
What is the recommended duloxetine regimen for managing anxiety, depression, and neuropathic pain during pregabalin withdrawal?
How should I manage dyspepsia and throat discomfort that began after starting regular omalizumab injections, given that I have been on a proton‑pump inhibitor for the past 3–4 months?
What are the definition, etiology, risk factors, pathophysiology, clinical features, scoring systems, investigations, management, complications, prognosis, and differential diagnoses for necrotizing fasciitis?
What is the likely cause and recommended management for dyspepsia and throat discomfort in a patient whose duodenal biopsies are normal and gastric antrum shows only mild chronic gastritis without Helicobacter pylori, atrophy, intestinal metaplasia, dysplasia, or granulomas?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.